Gillian M. Lamont

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2014 · 590 citations · Full text

Genetics, Pathology, Clinical Candidate +18

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

Jacqueline H. L. Fok, Antonio Ramos‐Montoya, Mercedes Vázquez–Chantada et al. · Nature Communications · 2019 · 327 citations · Full text

The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-<i>a</i>]pyridin-6-yl)amino]-9-(tetrahydro-2<i>H</i>-pyran-4-yl)-7,9-dihydro-8<i>H</i>-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor

Frederick W. Goldberg, M. Raymond V. Finlay, Attilla Ting et al. · Journal of Medicinal Chemistry · 2019 · 77 citations · Full text

Pharmacotherapy, Chemical Biology, Dna-pk Catalytic Subunit +20

Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS^G12C

Jason G. Kettle, Sharan K. Bagal, Sue Bickerton et al. · Journal of Medicinal Chemistry · 2022 · 56 citations · Full text

Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology

Frederick W. Goldberg, Jason G. Kettle, Gillian M. Lamont et al. · Journal of Medicinal Chemistry · 2022 · 53 citations · Full text